TargetMol

Bamocaftor

Product Code:
 
TAR-T30293
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30293-1mg1mg£369.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30293-5mg5mg£787.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30293-10mg10mg£1,050.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30293-1mL1 mL * 10 mM (in DMSO)£1,107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30293-25mg25mg£1,508.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30293-50mg50mg£2,022.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30293-100mg100mg£2,705.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Bamocaftor is a CFTR channel (DeltaF508-CFTR Mutant) corrector in patients with Cystic Fibrosis who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene, or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to tezacaftor, ivacaftor, or tezacaftor/ivacaftor and also in combination with tezacaftor and VX-561 in F508del/MF in patients with cystic fibrosis.
CAS:
2204245-48-5
Formula:
C28H32F3N5O4S
Molecular Weight:
591.65
Pathway:
Membrane transporter/Ion channel
Purity:
0.98
SMILES:
[H][C@@]1(C)CN(c2nc(ccc2C(=O)NS(=O)(=O)c2ccccc2)-n2ccc(OCCC3(CC3)C(F)(F)F)n2)C(C)(C)C1
Target:
CFTR

References

1. Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL. CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros. 2019 Jan;18(1):22-34. doi: 10.1016/j.jcf.2018.05.004. Epub 2018 Jun 20. Review. PubMed PMID: 29934203; PubMed Central PMCID: PMC6301143. 2. Grasemann H. CFTR Modulator Therapy for Cystic Fibrosis. N Engl J Med. 2017 Nov 23;377(21):2085-2088. doi: 10.1056/NEJMe1712335. Epub 2017 Nov 3. PubMed PMID: 29099349. 3. Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol. 2017 Nov;52(S48):S4-S14. doi: 10.1002/ppul.23773. Epub 2017 Sep 7. Review. PubMed PMID: 28881097; PubMed Central PMCID: PMC6208153.